that’s spot on, growth via acquisition is perfectly fine, but don’t overpay.
looking at how BKL has trended over the last 12 months suggests the EBITDA multiple, even against forecast FY19 was way too much.
Ann: Termination of the Bio-E Share Sale Agreement, page-4
Add S66 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $20.26M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4129 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 4129 | 1 |
View Market Depth
| Last trade - 16.12pm 02/10/2024 (20 minute delay) ? |
| S66 (ASX) Chart |
Day chart unavailable